Ladenburg lowered the firm’s price target on Beyond Air to $4 from $19 and keeps a Buy rating on the shares based on the lower revenue guidance and an extended timeline for Beyond Air’s pipeline programs, citing the company’s reduced fiscal 2025 revenue outlook. The soft launch of the LungFit PH nitric oxide generator and delivery system continues to be impacted by delays in new customer growth, the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XAIR:
- Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Options Volatility and Implied Earnings Moves Today, June 24, 2024
- Options Volatility and Implied Earnings Moves This Week, June 24 – June 27, 2024
- XAIR Earnings this Week: How Will it Perform?
- Beyond Air® Appoints David Webster as Chief Commercial Officer